The DOI matches its Crossref record.
FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma
Open accessAbstract
On December 18, 2019, the FDA granted accelerated approval to enfortumab vedotin-ejfv (PADCEV; Astellas and Seattle Genetics) for treatment of patients with locally advanced or metastatic urothelial cancer who have previously received a programmed cell death protein 1 or programmed death ligand 1 inhibitor, and a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting. Substantial evidence of effectiveness for this application is obtained from Cohort 1 of the single-arm, multicenter Study EV-201. Patients received enfortumab vedotin (EV) 1.25 mg/kg (up to a maximum dose of 125 mg) intravenously on days 1, 8, and 15 of 28-day cycles until disease progression or unacceptable toxicity. Confirmed objective response rate in the 125-patient efficacy population determined by blinded independent central review was 44% [95% confidence interval (CI), 35.1–53.2], with complete responses in 12%. Median response duration was 7.6 months (95% CI, 6.3–not estimable). Grade 3–4 adverse reactions occurred in 73% of patients. Hyperglycemia, peripheral neuropathy, ocular disorders, skin reactions, infusion site extravasations, and embryo-fetal toxicity are labeled as warnings and precautions for EV. The article summarizes the data and the FDA thought process supporting accelerated approval of EV. This approval may be contingent upon verification and description of clinical benefit in confirmatory trial(s).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Antibody drug conjugate: the “biological missile” for targeted cancer therapy
Fu, Z., Li, S., Han, S., Shi, C., & Zhang, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00947-7 · Cited by 1,643
Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability
Nguyen, T. D., Bordeau, B. M., & Balthasar, J. P. (2023) · Cancers · doi:10.3390/cancers15030713 · Cited by 441
Antibody–drug conjugates: Recent advances in linker chemistry
Su, Z., Xiao, D., Xie, F., Liu, L., Wang, Y., Fan, S., Zhou, X., & Li, S. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.03.042 · Cited by 403
Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies
Tarantino, P., Carmagnani Pestana, R., Corti, C., Modi, S., Bardia, A., Tolaney, S. M., Cortes, J., Soria, J., & Curigliano, G. (2022) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21705 · Cited by 385
The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial Carcinoma
Cathomas, R., Lorch, A., Bruins, H. M., Compérat, E. M., Cowan, N. C., Efstathiou, J. A., Fietkau, R., Gakis, G., Hernández, V., Espinós, E. L., et al. (2022) · European Urology · doi:10.1016/j.eururo.2021.09.026 · Cited by 295
Metadata
- Authors
- Chang, E., Weinstock, C., Zhang, L., Charlab, R., Dorff, S. E., Gong, Y., Hsu, V., Li, F., Ricks, T. K., Song, P., Tang, S., Waldron, P. E., Yu, J., Zahalka, E., Goldberg, K. B., Pazdur, R., Theoret, M. R., Ibrahim, A., & Beaver, J. A.
- Venue
- Clinical Cancer Research
- Published
- 2021-02-15
- Volume
- 27
- Issue
- 4
- Pages
- 922-927
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W3087937382
- Cited by
- 189
- References
- 0
- FWCI
- 17.66
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-20-2275
- The paper
- Chang, E., Weinstock, C., Zhang, L., Charlab, R., Dorff, S. E., Gong, Y., Hsu, V., Li, F., Ricks, T. K., Song, P., Tang, S., Waldron, P. E., Yu, J., Zahalka, E., Goldberg, K. B., Pazdur, R., Theoret, M. R., Ibrahim, A., & Beaver, J. A. (2021). FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-20-2275
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.